These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmaceutical Research and Manufacturers of America v. Walsh: the Supreme Court allows the states to proceed with expanding access to drugs. Jost TS Yale J Health Policy Law Ethics; 2004; 4(1):69-84. PubMed ID: 15052860 [No Abstract] [Full Text] [Related]
4. Maine racks up another win. High court advised not to hear case against law. Tieman J Mod Healthc; 2002 Jun; 32(23):20-1. PubMed ID: 12096424 [No Abstract] [Full Text] [Related]
6. Challenging pharmaceutical industry political power in Maine and Vermont. Castellblanch R J Health Polit Policy Law; 2003 Feb; 28(1):109-32. PubMed ID: 12705419 [TBL] [Abstract][Full Text] [Related]
7. These doctor's mission: keeping drug costs down. Guglielmo WJ Med Econ; 2001 Apr; 78(8):108-10, 113-6. PubMed ID: 11386066 [No Abstract] [Full Text] [Related]
8. High court gives green light to Maine Rx. Ranta-Williams K Revolution (Oakl); 2003; 4(3):4. PubMed ID: 12961840 [No Abstract] [Full Text] [Related]
9. Crossing boundaries. Big Pharma stalls discounted Maine Rx drug program. White C Revolution (Oakl); 2002; 3(6):9. PubMed ID: 12599702 [No Abstract] [Full Text] [Related]
10. Drug industry sues states over prescription programs for low-income residents. Young D Am J Health Syst Pharm; 2002 Mar; 59(5):408. PubMed ID: 11887405 [No Abstract] [Full Text] [Related]
11. Executive summary: pharmaceutical discounts under federal law: state program opportunities. von Oehsen WH; Ashe M; Duke K Am J Health Syst Pharm; 2003 Mar; 60(6):551-3. PubMed ID: 12659056 [No Abstract] [Full Text] [Related]
13. The pharmaceutical industry versus Medicaid--limits on state initiatives to control prescription-drug costs. Mello MM; Studdert DM; Brennan TA N Engl J Med; 2004 Feb; 350(6):608-13. PubMed ID: 14762190 [No Abstract] [Full Text] [Related]
14. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
15. Estimates of the Number of Brand-name Drugs Affected by the Medicaid Rebate Cap in 2017. Dickson S JAMA Intern Med; 2019 Mar; 179(3):437-439. PubMed ID: 30667469 [TBL] [Abstract][Full Text] [Related]
16. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology. American Society of Clinical Oncology J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877 [No Abstract] [Full Text] [Related]
17. Trying to get control of drug costs, Florida earns kudos--and a lawsuit. Carlson B Manag Care; 2001 Oct; 10(10):17, 21. PubMed ID: 11764743 [No Abstract] [Full Text] [Related]
18. US government supports Maine law to curb drug prices. Josefson D BMJ; 2002 Jun; 324(7351):1416. PubMed ID: 12068860 [No Abstract] [Full Text] [Related]
19. Supreme Court turns down PBMs. Fight continues over disclosure of drug discounts. Mantone J Mod Healthc; 2006 Jun; 36(24):16. PubMed ID: 16792265 [No Abstract] [Full Text] [Related]
20. Lowering Part D drug costs without direct CMS negotiations. Sipkoff M Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203 [No Abstract] [Full Text] [Related] [Next] [New Search]